Lv1
58 积分 2024-09-30 加入
MA11.04 First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study
17小时前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
19小时前
已完结
Deciphering the different phases of preclinical inflammatory bowel disease
20天前
已完结
FcRECEPTOR BIOLOGY
27天前
已完结
Systemic lupus erythematosus
1个月前
已完结
EGFR signaling pathway as therapeutic target in human cancers
2个月前
已完结
皖公网安备34019202002308
